In pure matrigel implantsnot containing cancer cells, mEHT treatment resulted in a significantincrease of CD45-CD31+ (endothelial) cells as compared to the sham-treatedmatrigel (Figure 4A).We also observed significant CD-105 downregulation 12 h after mEHTtreatment, with gradual recovery thereafter (Figure 4B). Here, PTPRC is linked to cancer.